| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Brian Corvese is Director at AGEN, with reported holdings spanning 2 companies. Brian Corvese's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $1.2M at current prices.
Brian Corvese's largest disclosed position is in AGEN as Director, worth about $614K.
Brian Corvese has 43 Form 4 filings on record from June 2015 to September 2026, across 3 companies: Director at MiNK Therapeutics (INKT), 2022–2026; Director at Agenus (AGEN), 2015–2026; Director at Protagenic Therapeutics, Inc.\new (PTIX), 2017–2024.
The 50 reported transactions were 30 option or other derivative awards, 17 stock awards and 3 option exercises.
There are no priced open-market purchases or sales on record, so none of these filings shows a decision to buy or sell shares in the market.
No transactions found
Try adjusting your filters or search criteria